Blai Coll
Chief Medical OfficerDr. Blai Coll, M.D., Ph.D., is Chief Medical Officer of Structure Therapeutics Inc. from September 18, 2024 and served as Vice President of Clinical Development since 2022 until September 18, 2024, leading the GSBR-1290 program. Dr. Coll is a physician-scientist with extensive experience in clinical development. Dr. Coll was Vice President of Endocrine and Metabolism Clinical Development at Structure Therapeutics, where he led the company’s clinical development activities for GSBR-1290. Before joining Structure, Dr. Coll was at Amgen where he held different leadership positions in the cardiovascular group, including management of lifecycle studies for Repatha® (open label extension studies with more than 6,000 patients) and early development projects in the cardiovascular space. Before joining Amgen, Dr. Coll served as Medical Director at AbbVie, leading the late-stage atrasentan clinical program for chronic kidney disease, including a Phase 3 multinational outcomes study. Dr. Coll earned his medical degree from Universitat Autonoma de Barcelona School of Medicine and a Ph.D. from Universitat Rovira i Virgili.
Positions
- Company NameStructure Therapeutics Inc.Stock CodeGPCRPositionChief Medical OfficerColleagues
- RCRaymond C. StevensCEO & Director
- DGDaniel G. WelchIndependent Chairman
- JSJun S. YoonCo- Founder, CFO & Secretary
- YMYingli MaChief Technology Officer
- XLXichen LinChief Scientific Officer & GM of Structure Shanghai
- SESharon Elizabeth TetlowIndependent Director
- TWTed W. LoveIndependent Director
- ELEric L. DobmeierIndependent Director
